Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy
出版年份 2011 全文链接
标题
Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy
作者
关键词
-
出版物
JOURNAL OF NEURO-ONCOLOGY
Volume 107, Issue 1, Pages 197-205
出版商
Springer Nature
发表日期
2011-10-21
DOI
10.1007/s11060-011-0737-8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
- (2011) Wei Xu et al. CANCER CELL
- 2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP+-Dependent Isocitrate Dehydrogenase Mutations
- (2011) Genglin Jin et al. PLoS One
- Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome
- (2011) Z. J. Reitman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation
- (2010) W. C. Chou et al. BLOOD
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
- (2010) Patrick S. Ward et al. CANCER CELL
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
- (2010) Roel G.W. Verhaak et al. CANCER CELL
- IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
- (2010) M. J. van den Bent et al. CLINICAL CANCER RESEARCH
- Prognostic markers in gliomas
- (2010) Marianne Labussiere et al. Future Oncology
- Molecular signatures classify astrocytic gliomas byIDH1mutation status
- (2010) Grischa Toedt et al. INTERNATIONAL JOURNAL OF CANCER
- Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
- (2010) Stefan Gross et al. JOURNAL OF EXPERIMENTAL MEDICINE
- IDH mutations in glioma and acute myeloid leukemia
- (2010) Lenny Dang et al. TRENDS IN MOLECULAR MEDICINE
- Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
- (2009) Christian Hartmann et al. ACTA NEUROPATHOLOGICA
- IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas
- (2009) Takuya Watanabe et al. AMERICAN JOURNAL OF PATHOLOGY
- IDH1mutations at residue p.R132 (IDH1R132) occur frequently in high-grade gliomas but not in other solid tumors
- (2009) Fonnet E. Bleeker et al. HUMAN MUTATION
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
- (2009) Lenny Dang et al. NATURE
- IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide
- (2009) H. J. Dubbink et al. NEUROLOGY
- IDH1andIDH2Mutations in Gliomas
- (2009) NEW ENGLAND JOURNAL OF MEDICINE
- IDH1andIDH2Mutations in Gliomas
- (2009) Hai Yan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of the IDH1 codon 132 mutation in brain tumors
- (2008) Jörg Balss et al. ACTA NEUROPATHOLOGICA
- The principles of quantification applied to in vivo proton MR spectroscopy
- (2008) Gunther Helms EUROPEAN JOURNAL OF RADIOLOGY
- Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review
- (2008) Mahdi Aghili et al. JOURNAL OF NEURO-ONCOLOGY
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- (2008) D. W. Parsons et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now